News >

Esteva Explains State of Genomic Testing in Breast Cancer

Danielle Bucco
Published: Tuesday, Aug 22, 2017

Francisco J. Esteva, MD, PhD

Francisco J. Esteva, MD, PhD
Physicians must continue to develop an understanding of breast cancer tissue and plasma to personalize medicine and deliver the optimal treatment to their patients, says Francisco J. Esteva, MD, PhD, who spoke on genomic testing at the 16th Annual International Congress on the Future of Breast Cancer® (East).

In an interview during the meeting, Esteva, a professor in the Department of Medicine at NYU Langone Medical Center, discussed the clinical implications of genomic testing for patients with metastatic breast cancer.

OncLive: What are the clinical implications of genomic testing in breast cancer?

Esteva: There are different technologies that are being used to profile both primary and metastatic breast cancer tumors including next-generation sequencing, circulating-free DNA in the plasma, and other technologies looking at the microenvironment. In my presentation, I just focused on next-generation sequencing and liquid biopsies. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x